State Street’s Turnstone Biologics TSBX Stock Holding History

State Street’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-38,491	Closed	-$101K	–	4398
2024 Q1	$101K	Buy	38,491 +4,642	+14%	+$13.3K	﹤0.01%	4030
2023 Q4	$86.1K	Buy	33,849 +10,349	+44%	+$27K	﹤0.01%	4081
2023 Q3	$92.6K	Buy	+23,500	New	+$209K	﹤0.01%	4132

Other funds holding TSBX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

State Street's TSBX Position: Q2 2024 in Review

State Street sold out of Turnstone Biologics (TSBX) in Q2 2024, closing a stake of 38,491 shares — an estimated $101K sold.

State Street first reported a position in TSBX in Q3 2023 and held it in 3 quarters. The position peaked at $101K in Q1 2024. 47 funds tracked by Wall St. Rank hold TSBX as of Q2 2024.

State Street reported no remaining Turnstone Biologics position as of Q2 2024 after selling out during the quarter.
State Street sold 38,491 Turnstone Biologics shares in Q2 2024, an estimated $101K.
State Street first reported a position in Turnstone Biologics in Q3 2023 and held it in 3 quarters.
State Street's Turnstone Biologics position peaked at $101K in Q1 2024.
47 funds tracked by Wall St. Rank held Turnstone Biologics as of Q2 2024.

Based on State Street's 13F filing for Q2 2024, filed 14 Aug 2024.